Related Experiment Videos
[BRAF gene mutation in thyroid cancer].
Ewa Kopczyńska1, Roman Junik, Tomasz Tyrakowski
1Uniwersytet Mikołaja Kopernika w Toruniu, Collegium Medicum w Bydgoszczy. kopczynska@cm.umk.pl
Summary
The BRAF gene mutation, specifically T1796A, is common in papillary thyroid cancer and may serve as a diagnostic marker. This mutation is linked to poorer patient outcomes and aggressive disease characteristics.
Area of Science:
- Oncogenic signaling pathways
- Molecular genetics of cancer
Context:
- Papillary thyroid cancer (PTC) development involves mutations in cell growth pathways like RET/PTC-RAS-RAF-MEK-ERK.
- BRAF gene mutations are frequently observed in various carcinomas, notably malignant melanomas and PTC.
Purpose:
- To investigate the role and significance of BRAF gene mutations in papillary thyroid cancer.
- To evaluate BRAF as a potential diagnostic and prognostic biomarker for PTC.
Summary:
- The most common BRAF mutation (T1796A) leads to constitutive activation of BRAF kinase (V599E).
- This specific BRAF mutation is found in PTC but not in follicular thyroid cancer or benign adenomas, suggesting diagnostic potential.
- BRAF mutations correlate with unfavorable prognostic factors, including extrathyroidal invasion and distant metastasis.
Impact:
- Mutated BRAF may serve as a sensitive and specific molecular marker for diagnosing papillary thyroid cancer.
- BRAF mutation status can act as a prognostic biomarker, identifying patients with a higher risk of aggressive disease and metastasis.